RayKnowChina Research Map
Shortlist0

RecruitingIdiopathic pulmonary fibrosisPhase 3

Registered title, quoted from ClinicalTrials.gov

Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

An open trial on idiopathic pulmonary fibrosis, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 45 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 45

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Inner Mongolia Medical University内蒙古医科大学附属医院HohhotHospital page
  2. Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
  3. Study siteAnhui Chest Hospital安徽省胸科医院HefeiHospital page
  4. Study siteBeijing Chao-Yang Hospital首都医科大学附属北京朝阳医院BeijingHospital page
  5. Study siteBeijing Friendship Hospital首都医科大学附属北京友谊医院BeijingHospital page
  6. Study siteFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
  7. Study siteFirst Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院GuangzhouHospital page
  8. Study siteFirst Affiliated Hospital of Ningbo University宁波大学附属第一医院NingboHospital page
  9. Study siteFirst Affiliated Hospital of Shandong First Medical University山东第一医科大学第一附属医院(山东省千佛山医院)JinanHospital page
  10. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  11. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  12. Study siteFirst Affiliated Hospital of Xi'an Medical College西安医学院第一附属医院Xi'anHospital page
  13. Study siteFirst Affiliated Hospital of Xinjiang Medical University新疆医科大学第一附属医院UrumqiHospital page
  14. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  15. Study siteFirst People Hospital昆明市第一人民医院KunmingHospital page
  16. Study siteFuzhou University Affiliated Provincial Hospital福州大学附属省立医院FuzhouHospital page
  17. Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
  18. Study siteHangzhou First People's Hospital杭州市第一人民医院HangzhouHospital page
  19. Study siteHebei Medical University Third Hospital河北医科大学第三医院ShijiazhuangHospital page
  20. Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
  21. Study siteJiangxi Provincial People' Hospital江西省人民医院NanchangHospital page
  22. Study siteNanfang Hospital南方医科大学南方医院GuangzhouHospital page
  23. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  24. Study siteNanyang First People's Hospital南阳市第一人民医院NanyangHospital page
  25. Study siteNingbo Medical Center Lihuili Hospital宁波市医疗中心李惠利医院NingboHospital page
  26. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  27. Study siteQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page
  28. Study siteRenmin Hospital of Wuhan University武汉大学人民医院WuhanHospital page
  29. Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
  30. Study siteSecond Affiliated Hospital of Xiamen Medical College厦门市第二医院XiamenHospital page
  31. Study siteSecond Hospital of Hebei Medical University河北医科大学第二医院ShijiazhuangHospital page
  32. Study siteSecond Hospital of Jilin University吉林大学第二医院ChangchunHospital page
  33. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  34. Study siteShanghai Pulmonary Hospital, Tongji University上海市肺科医院ShanghaiHospital page
  35. Study siteShanxi Bethune Hospital山西白求恩医院TaiyuanHospital page
  36. Study siteShengjing Hospital of China Medical University中国医科大学附属盛京医院ShenyangHospital page
  37. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  38. Study siteSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page
  39. Study siteTianjin Chest Hospital天津市胸科医院TianjinHospital page
  40. Study siteTianjin Medical University General Hospital天津医科大学总医院TianjinHospital page
  41. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  42. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  43. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  44. Study siteYichang Central People's Hospital宜昌市中心人民医院YichangHospital page
  45. Study siteYuncheng Central Hospital版权所有 运城市中心医院YunchengHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07687459, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 40 years to Not stated; sex: all

    Registered eligibility fields

  2. Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.

    Inclusion criterion 3

  3. not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.

    Inclusion criterion 11

    Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.

    Inclusion criterion 12

    Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.

    Exclusion criterion 16

    Patients (female) who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study (for female)

    Exclusion criterion 25

  4. DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.

    Inclusion criterion 8

    Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.0 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.

    Exclusion criterion 10

  5. Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.

    Exclusion criterion 17

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07687459, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • An informed consent form (ICF) signed and dated at screening (Visit 1), prior to initiation of any study related procedures, and in accordance with ICH-GCP and local legislation.
  • Patients aged ≥40 years at time of signing the ICF.
  • Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.
  • UIP or probable UIP with fibrosis extent >10% at HRCT.
  • Meet all the following criteria during the screening period:
  • FVC ≥45% predicted of normal
  • FEV1/FVC ≥0.7
  • DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.
  • Background antifibrotic therapies are allowed, patients may be either:
  • on monotherapy with nintedanib or pirfenidone must have been on a stable therapy for at least 12 weeks prior to randomization.
  • not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.
  • Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.

Exclusion criteria:

  • Interstitial lung disease associated with known primary diseases (eg, autoimmune disease-related interstitial lung diseases, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos, and coal dust), or drugs (eg, amiodarone).
  • Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent (or within 8 weeks when half-life is unknown) prior to screening is not allowed.
  • Pulmonary hypertension that is clinically relevant or severe as deemed by the investigator, or other clinically significant pulmonary abnormalities.
  • Unstable cardiovascular or other disease within 6 months prior to the screening visit or during the screening period.
  • Presence of other clinically significant airway disease that may, in the opinion of the investigator, impact the study safety or efficacy objectives, such as asthma, bronchiectasis, cystic fibrosis, active aspergillosis, active tuberculosis, or other serious concomitant respiratory disorder other than pulmonary fibrosis.
  • Acute exacerbation of IPF within 6 months prior to screening visit and/or during the screening period.
  • Patients with underlying chronic liver disease (Child Pugh A, B, or C hepatic impairment), and patients with non-alcoholic steatohepatitis.
  • Patients with hyperbilirubinemia or Gilbert's syndrome.
  • Relevant chronic or acute infections including human immunodeficiency virus (HIV) and clinically significant viral hepatitis.
  • Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.0 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.
  • Estimated glomerular filtration rate <60 mL/min/1.73m2 at screening.
  • Patient with 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF) >450 ms for males and >470 ms for females at screening (Visit 1).
  • Patient with a history of lung volume reduction surgery or lung transplant.
  • Current smoker and/or cotinine (smoking) test positive.
  • History of drug abuse, drug use, or alcohol abuse within the past 3 months.
  • Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.
  • Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.
  • Use of any of the following therapies within 4 weeks prior to screening visit and during the screening period or planned during the study: warfarin and immunosuppressive medications.
  • Patients currently taking endothelin receptor antagonists,phosphodiesterase type 5 inhibitors, soluble guanylate cyclase modulators, prostacyclin analogues and prostanoids, or activin signaling inhibitor.
  • Patients currently on a treatment with nerandomilast within 8 weeks prior to screening visit and during the screening period.
  • Use of any of the following drugs within 2 weeks prior to Visit 1/screening or planned during the duration of the study
  • Strong and moderate cytochrome P450 3A4 or 1A2 inhibitors/inducers
  • Medications associated with substantial risk for prolongation of corrected QT interval.
  • Patients who have consumed grapefruit or grapefruit juice, pomelo, Seville orange or Seville orange-containing products within 48 hours before Day 1.
  • Patients (female) who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study (for female)
  • Patients with known hypersensitivity or contraindications to serine/threonine kinase inhibitors.
  • Any condition that would interfere with the interpretation of study assessments or impair study participation.
  • Any physical or psychological conditions or circumstance that, in the opinion of the investigator, may make a patient unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.

Quoted from ClinicalTrials.gov, NCT07687459, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07687459, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07687459